Kiora Pharmaceuticals, Inc. (KPRX)

0.5133 -0.0220 (-4.11%) At close: 04:00PM EDT

Kiora Pharmaceuticals, Inc.

332 Encinitas Boulevard
Suite 102
Encinitas, CA 92024
United States
858 224 9600
https://www.kiorapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Brian M. Strem Ph.D.	President, CEO & Director	586k	N/A	1980
Ms. Melissa Tosca CPA	Executive Vice President of Finance	324.48k	N/A	1981
Dr. Eric J. Daniels M.B.A., M.D.	Chief Development Officer	456.16k	N/A	1974
Dr. Stefan Sperl Ph.D.	Executive Vice President of CMC & Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Corporate governance

Kiora Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.